Fig. 2
From: CRISPR–Cas9 applications in T cells and adoptive T cell therapies
Two clinical trials with TIL therapy procedure: tumor surgical specimens were minced into fragments and followed by the isolation of T cells. TILs were cultured in a rapid expansion with high dose IL-2, and genome editing was processed by CRISPR–Cas9 to target PD1. The patient next to receive the TILs therapies needed to undergo nonmyeloablative lympho-depleting chemotherapy previously, and then the expanded TILs were infused via a single intravenous dose and then continued to inject high dose IL-2 to maintain TIL persistence